WEBULL
News
SONN
1.260
0.00%
0.00
Hyperliquid Strategies And Sonnet BioTherapeutics Complete Business Combination; New Company To Trade on Nasdaq As "PURR" While Sonnet Becomes A Wholly Owned Subsidiary
Benzinga · 12/02 21:31
Press Release: Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Dow Jones · 12/02 21:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/02 21:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/02 17:05
Sonnet BioTherapeutics Approves Merger with Hyperliquid and Rorschach
TipRanks · 12/02 14:43
Sonnet BioTherapeutics stockholders approve Hyperliquid Strategies combination
TipRanks · 12/02 14:25
Sonnet BioTherapeutics Stockholders Approve Business Combination With Hyperliquid Strategies And Rorschach I
Benzinga · 12/02 14:23
Press Release: Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dow Jones · 12/02 14:17
Weekly Report: what happened at SONN last week (1124-1128)?
Weekly Report · 12/01 10:24
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb
NASDAQ · 12/01 03:29
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/28 21:06
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Seeking Alpha · 11/28 18:30
Weekly Report: what happened at SONN last week (1117-1121)?
Weekly Report · 11/24 10:30
Catalyst Watch: Alibaba earnings, AI anxiety, airline M&A, and a Burry teaser
Seeking Alpha · 11/21 20:00
Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean.
NASDAQ · 11/19 17:08
Sonnet BioTherapeutics Adjourns Meeting for Business Combination
TipRanks · 11/18 14:48
Sonnet BioTherapeutics announces adjournment of special meeting
TipRanks · 11/18 14:45
Weekly Report: what happened at SONN last week (1110-1114)?
Weekly Report · 11/17 10:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/14 12:06
Weekly Report: what happened at SONN last week (1103-1107)?
Weekly Report · 11/10 10:27
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).